ArticleActa neuropathologica communications2018
Tectal glioma as a distinct diagnostic entity: a comprehensive clinical, imaging, histologic and molecular analysis.
Article in Acta neuropathologica communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Management strategies for pediatric patients with tectal gliomas: a systematic review.Neurosurgical review · 2022Pooled it
- Tectal glioma versus pilocytic astrocytoma: revisiting tumor classification in light of molecular heterogeneity.Acta neuropathologica · 2026Article
- Case Report: Identification of rareFrontiers in oncology · 2026Article
- Histopathology and Molecular Pathology of Pineal Region Tumors.Advances and technical standards in neurosurgery · 2026Review
- Imaging of Pineal Region Masses.Advances and technical standards in neurosurgery · 2026Review
- Activated signaling pathways and metabolic processes in disseminating myxoid glioneuronal tumors.Journal of neuropathology and experimental neurology · 2025Article
- Tectal gliomas as a rare finding in presumed idiopathic congenital aqueductal stenosis: patient series.Journal of neurosurgery. Case lessons · 2025Article
- Article
- Tectal glioma: clinical, radiological, and pathological features, and the importance of molecular analysis.Brain tumor pathology · 2025Article
- Modern Radiation Treatment Planning Parameters and Outcomes in Pediatric Tectal Gliomas.Advances in radiation oncology · 2024Article
- Treatment of Pediatric Low-Grade Gliomas.Current neurology and neuroscience reports · 2023Review
- The molecular characteristics of low-grade and high-grade areas in desmoplastic infantile astrocytoma/ganglioglioma.Neuropathology and applied neurobiology · 2022Article
- Molecular analyses of rosette-forming glioneuronal tumor of the midbrain tegmentum: A report of two cases and a review of the FGFR1 status in unusual tumor locations.Surgical neurology international · 2022Article
- Radiohistogenomics of pediatric low-grade neuroepithelial tumors.Neuroradiology · 2021Review
- MRI-based diagnosis and treatment of pediatric brain tumors: is tissue sample always needed?Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Review
- Novel KRAS mutation in an unusual tectal low-grade glioma.BMJ case reports · 2021Article
- Freiburg Neuropathology Case Conference: : Blurred Vision and Headaches in a 15-year-old Boy.Clinical neuroradiology · 2020Article
- Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.Acta neuropathologica communications · 2020Article
- Tectal glioma harbors high rates of KRAS G12R and concomitant KRAS and BRAF alterations.Acta neuropathologica · 2020Article
- Pineal Gland Tumor Microenvironment.Advances in experimental medicine and biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Tectal glioma (TG) is a rare low-grade tumor occurring predominantly in the pediatric population. There has been no detailed analysis of molecular alterations in TG. Risk factors associated with inferior outcome and long-term sequelae of TG have not been well-documented. We retrospectively studied TGs treated or referred for review at St. Jude Children's Research Hospital (SJCRH) between 1986 and 2013. Longitudinal clinical data were summarized, imaging and pathology specimen centrally reviewed, and tumor material analyzed with targeted molecular testing and genome-wide DNA methylation profiling. Forty-five patients with TG were included. Twenty-six (57.8%) were male. Median age at diagnosis was 9.9 years (range, 0.01-20.5). Median follow-up was 7.6 years (range, 0.5-17.0). The most common presenting symptoms were related to increased intracranial pressure. Of the 22 patients treated at SJCRH, 19 (86%) required cerebrospinal fluid diversion and seven (32%) underwent tumor-directed surgery. Five patients (23%) received radiation therapy and four (18%) systemic therapy. Ten-year overall and progression-free survival were 83.9 ± 10.4% and 48.7 ± 14.2%, respectively. Long-term morbidities included chronic headaches, visual symptoms and neurocognitive impairment. Lesion ≥3cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.